The Colossus Johnson & Johnson chooses to invest in Italy a staggering figure: 580 million euros of which 125 will support an increase in production capacity and build skills for the future: this is the impressive sum that Johnson & Johnson Innovative Medicine will invest in Italy over the next five years.
Data from Johnson & Johnson in Italy
The advert is placed inside a Strategic Plan which predicted investment growth in Italy of 9.2% each year in the period 2019-2023, three times higher than the pharmaceutical sector average, according to a new study by The European House Ambrosetti. This has translated into a 15% increase in employment in Italy over the last five years, reaching approximately 1,400 employees across the country. “Johnson & Johnson – added Oladapo Ajayi, vice president, Innovative Medicine Supply Chain of Johnson & Johnson – has a significant manufacturing presence throughout Europe and the Latina site is an important part of our global network. Let’s keep doing important investments in our Supply Chain to support the growth of our current portfolio of medicines and our pipeline of innovative solutions, which will allow us to continue to provide products to the millions of patients around the world who rely on us every day.”
The turnover in the pharmaceutical sector
In the pharmaceutical landscape, Johnson & Johnson stands out for its strong focus on Research and development (R&D): in the last five years, the company has invested almost 50 million euros in Italy (+11.7% every year since 2019). Investments in R&D also foster a strong commitment to scientific research in the country. In 2023, Johnson & Johnson Innovative Medicine managed 114 clinical studies and collaborated with 993 research centers in Italyoffering access to care to more than 5,000 patients.
The focus is on Latina
The Latina site, which represents an important part of Johnson & Johnson’s global supply chain, produces more than four billion tablets per year, for around 30 different products, and 97% of production is exported, reaching patients all over the world. The investment plan will allow an increase in production capacity by over 25%, as it will include innovative projects to support products under development and new production technologiessuch as the Flex Line, to more efficiently manage the packaging of small production batches and a new continuous production line that will reduce the total end-to-end production time and allow drugs to reach patients more quickly.
“The Johnson & Johnson plant in Latina, Italy, is experiencing a significant evolution – stated the General Manager of the Johnson & Johnson plant in Latina, Jorge Lopez – as we are strengthening our capabilities to serve a greater number of patients with innovative products. It has been recognized as a 4IR (Industry 4.0) site since World Economic Forum thanks to our commitment to innovation and sustainability. This is a truly exciting time for our site. We have very passionate and committed people who focus on safety, quality and reliability as we work to deliver medicines to patients around the world every day.”
